Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mahamaya LifesciencesBOM:544611 16 Market Cap is ₹3,896 Mil as of Aug. 02, 2026. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review. Among 265 Agriculture companies, Mahamaya Lifesciences ranks worse than 69.43% on this metric.
Mahamaya Lifesciences's quarterly market cap
stayed the same
from Sep. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then
increased
from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹3,522 Mil).
Mahamaya Lifesciences's annual market cap
stayed the same
from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then
increased
from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹3,522 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mahamaya Lifesciences's Enterprise Value for Today is ₹4,409 Mil.
Mahamaya Lifesciences (BOM:544611) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544611 vs CTVA, CF, MOS: Market Cap Comparison
For the Agricultural Inputs subindustry, Mahamaya Lifesciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mahamaya Lifesciences Market Cap vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Mahamaya Lifesciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mahamaya Lifesciences's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mahamaya Lifesciences (BOM:544611) has a Market Cap of ₹3,896 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mahamaya Lifesciences and its competitors. According to the industry distribution chart, Mahamaya Lifesciences ranks #184 out of 265 companies in the Agriculture industry, placing it in the top 69.4%.
Is Mahamaya Lifesciences' Market Cap too high?
Mahamaya Lifesciences' current Market Cap is ₹3,896 Mil. Based on the distribution chart, Mahamaya Lifesciences ranks #184 out of 265 companies in the Agriculture industry, which is below the industry midpoint. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' Market Cap compare to CTVA and CF?
According to the Agriculture industry distribution chart, Mahamaya Lifesciences ranks #184 out of 265 companies for Market Cap. This places Mahamaya Lifesciences in the lower half of its industry. The industry median Market Cap is 195.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for an Agriculture company?
The median Market Cap among Agriculture companies is 195.20, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mahamaya Lifesciences and its competitors. For the Agriculture industry, the median Market Cap is 195.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mahamaya Lifesciences's current Market Cap is ₹3,896 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current Market Cap of ₹3,896 Mil. The current Market Cap is ₹3,896 Mil. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current Market Cap is ₹3,896 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score
Get the complete analysis for BOM:544611
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544611 has been successfully added to your 
